About Travere Therapeutics, Inc.
https://www.travere.comTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.
CEO
Eric M. Dube
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-11-02 | Reverse | 1:9 |
| 2009-07-02 | Reverse | 1:100 |
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
TD Cowen
Buy
Citigroup
Buy
Guggenheim
Buy
Canaccord Genuity
Buy
B of A Securities
Buy
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:10.6M
Value:$306.65M
ARMISTICE CAPITAL, LLC
Shares:8.88M
Value:$256.78M
BLACKROCK, INC.
Shares:8.1M
Value:$234.35M
Summary
Showing Top 3 of 261
About Travere Therapeutics, Inc.
https://www.travere.comTravere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $164.86M ▲ | $138.34M ▲ | $25.71M ▲ | 15.59% ▲ | $0.29 ▲ | $44.25M ▲ |
| Q2-2025 | $114.45M ▲ | $125.58M ▲ | $-12.76M ▲ | -11.14% ▲ | $-0.14 ▲ | $4.13M ▲ |
| Q1-2025 | $81.73M ▲ | $119.73M ▼ | $-41.23M ▲ | -50.44% ▲ | $-0.47 ▲ | $-25.53M ▲ |
| Q4-2024 | $74.79M ▲ | $132.97M ▲ | $-60.26M ▼ | -80.58% ▲ | $-0.73 ▼ | $-45.43M ▼ |
| Q3-2024 | $62.9M | $117.42M | $-54.81M | -87.14% | $-0.7 | $-40.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $254.53M ▼ | $538.58M ▼ | $465.02M ▼ | $73.56M ▲ |
| Q2-2025 | $319.54M ▼ | $555.31M ▲ | $522.56M ▲ | $32.75M ▼ |
| Q1-2025 | $322.24M ▼ | $548.8M ▼ | $515.98M ▼ | $32.82M ▼ |
| Q4-2024 | $370.7M ▲ | $594.13M ▲ | $535.05M ▲ | $59.08M ▲ |
| Q3-2024 | $277.44M | $504.41M | $534.86M | $-30.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $25.71M ▲ | $14.32M ▲ | $86.59M ▲ | $-65.34M ▼ | $35.78M ▲ | $14.18M ▲ |
| Q2-2025 | $-12.76M ▲ | $4.98M ▲ | $4.85M ▼ | $1.48M ▼ | $13.26M ▲ | $4.75M ▲ |
| Q1-2025 | $-41.23M ▲ | $-42.19M ▼ | $41.29M ▲ | $3.72M ▼ | $3.36M ▼ | $-53.98M ▼ |
| Q4-2024 | $-60.27M ▼ | $-35.72M ▲ | $-80.31M ▼ | $139.12M ▲ | $22.13M ▲ | $-45.28M ▲ |
| Q3-2024 | $-54.75M | $-42.51M | $46.13M | $46K | $4.12M | $-50.7M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q3-2025 | Q2-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $10.00M ▲ | $50.00M ▲ | $20.00M ▼ |
 Product | $0 ▲ | $80.00M ▲ | $110.00M ▲ | $0 ▼ |
 Royalty | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Eric M. Dube
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2012-11-02 | Reverse | 1:9 |
| 2009-07-02 | Reverse | 1:100 |
ETFs Holding This Stock
Summary
Showing Top 3 of 137
Ratings Snapshot
Rating : D+
Most Recent Analyst Grades
HC Wainwright & Co.
Buy
TD Cowen
Buy
Citigroup
Buy
Guggenheim
Buy
Canaccord Genuity
Buy
B of A Securities
Buy
Grade Summary
Showing Top 6 of 14
Price Target
Institutional Ownership
JANUS HENDERSON GROUP PLC
Shares:10.6M
Value:$306.65M
ARMISTICE CAPITAL, LLC
Shares:8.88M
Value:$256.78M
BLACKROCK, INC.
Shares:8.1M
Value:$234.35M
Summary
Showing Top 3 of 261